Expert Infection & Liver Disease Care in Shanghai
The Department of Infectious Disease and Hepatology at Ruijin Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of China's most distinguished centers for the management of viral hepatitis, liver disease, and complex infectious conditions. With particular strength in the treatment of chronic hepatitis B and C, liver cirrhosis, and emerging infectious diseases, the department combines outstanding clinical expertise with a productive research program that has contributed significantly to the global understanding and treatment of viral hepatitis.
For international patients seeking expert hepatology or infectious disease care in Shanghai — whether for chronic hepatitis B or C, liver cirrhosis, a complex infection, or a second opinion on a challenging diagnosis — Ruijin Hospital's department represents one of the most compelling destinations in Asia. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey.
About the Department
Ruijin Hospital's infectious disease and hepatology department is a national key clinical specialty with a long history of clinical excellence and research innovation. The department operates dedicated inpatient infectious disease and hepatology wards, an isolation unit for highly infectious diseases, a viral hepatitis clinic, a liver cirrhosis and portal hypertension clinic, a HIV/AIDS management service, and a travel medicine and tropical disease clinic.
The department's hepatology program is particularly distinguished, with decades of experience in the management of chronic hepatitis B and C — the two most common causes of liver cirrhosis and hepatocellular carcinoma in China. The department has been at the forefront of clinical trials evaluating novel antiviral therapies for hepatitis B and C, and has contributed to the development of national and international treatment guidelines. Faculty members publish regularly in leading hepatology and infectious disease journals including Journal of Hepatology, Hepatology, Gut, Lancet Infectious Diseases, and Clinical Infectious Diseases.
Conditions Treated
Viral Hepatitis
- Chronic Hepatitis B (CHB) — Comprehensive management including nucleos(t)ide analogues (tenofovir alafenamide, entecavir), pegylated interferon, and emerging therapies targeting HBsAg loss; treatment of HBeAg-positive and HBeAg-negative CHB; management of hepatitis B in special populations (pregnancy, immunosuppression, renal impairment)
- Hepatitis B Reactivation — Prevention and management of HBV reactivation in patients receiving immunosuppressive therapy, chemotherapy, or biologic agents
- Chronic Hepatitis C (CHC) — Pan-genotypic direct-acting antiviral (DAA) therapy (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir); cure rates >95% across all genotypes; management of DAA-experienced patients
- Hepatitis D (HDV) — Bulevirtide therapy for chronic hepatitis D; management of HBV/HDV co-infection
- Acute Viral Hepatitis — Hepatitis A, B, C, D, and E; management of acute liver failure
Liver Disease
- Liver Cirrhosis — Comprehensive management of compensated and decompensated cirrhosis; prevention and treatment of complications
- Portal Hypertension — Variceal screening and prophylaxis; endoscopic variceal ligation and sclerotherapy; TIPS coordination; ascites management
- Hepatic Encephalopathy — Acute and chronic HE management; rifaximin, lactulose, and BCAA therapy
- Spontaneous Bacterial Peritonitis (SBP) — Diagnosis and antibiotic management; SBP prophylaxis
- Hepatorenal Syndrome — Terlipressin and albumin therapy; renal replacement therapy coordination
- Acute-on-Chronic Liver Failure (ACLF) — Intensive management of acute decompensation; artificial liver support systems
- Autoimmune Hepatitis — Corticosteroid and azathioprine therapy; second-line agents for refractory disease
- Primary Biliary Cholangitis (PBC) — Ursodeoxycholic acid, obeticholic acid, and fibrate therapy
- Primary Sclerosing Cholangitis (PSC) — Endoscopic management of dominant strictures; liver transplantation evaluation
- Drug-Induced Liver Injury (DILI) — Diagnosis, causality assessment, and management
- Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) — Metabolic management; emerging pharmacotherapy
- Liver Transplantation Evaluation — Pre-transplant assessment and listing coordination with hepatobiliary surgery
Infectious Diseases
- HIV/AIDS — Antiretroviral therapy (ART) initiation and optimization; management of opportunistic infections; HIV/HBV and HIV/HCV co-infection
- Tuberculosis — Drug-sensitive and drug-resistant TB; extrapulmonary TB; TB/HIV co-infection
- Sepsis & Bacteremia — Source control, antibiotic stewardship, and intensive management of severe sepsis
- Multidrug-Resistant Organism (MDRO) Infections — MRSA, CRE, CRAB, and CRPA infections; novel antibiotic therapy (ceftazidime-avibactam, cefiderocol, imipenem-cilastatin-relebactam)
- Fever of Unknown Origin (FUO) — Systematic diagnostic workup for prolonged unexplained fever
- Tropical & Travel Medicine — Malaria, dengue, typhoid, and other travel-related infections; pre-travel vaccination and prophylaxis
- Parasitic Infections — Schistosomiasis, echinococcosis, and other parasitic diseases
- Immunocompromised Host Infections — Infections in transplant recipients, hematology patients, and patients on biologic therapy
Leading Specialist
Prof. Wei Lai (魏来) — Director, Infectious Disease & Hepatology
Prof. Wei Lai is one of China's most eminent hepatologists and a nationally and internationally recognized authority in viral hepatitis, liver cirrhosis, and the management of complex liver disease. As Director of the Department of Infectious Disease and Hepatology at Ruijin Hospital, he leads one of China's most productive hepatology clinical and research programs.
Prof. Wei is particularly recognized for his expertise in the management of chronic hepatitis B and C, including the use of novel antiviral therapies targeting HBsAg loss in hepatitis B and pan-genotypic DAA therapy for hepatitis C. He has been a key contributor to national and international hepatitis treatment guidelines, including the Chinese Society of Hepatology guidelines for chronic hepatitis B and C management, and has participated in multiple landmark clinical trials evaluating novel antiviral agents.
In liver cirrhosis management, Prof. Wei's program provides comprehensive care for patients with compensated and decompensated cirrhosis, including the management of portal hypertension complications, hepatic encephalopathy, and acute-on-chronic liver failure. His research on viral hepatitis, liver fibrosis, and cirrhosis complications has been published in leading journals including Journal of Hepatology, Hepatology, and Gut.
Hepatitis B: Toward a Functional Cure
Ruijin's hepatitis B program is at the forefront of efforts to achieve functional cure — defined as sustained HBsAg loss after treatment — in chronic hepatitis B patients. The program offers:
- Optimized Nucleos(t)ide Analogue Therapy — Tenofovir alafenamide (TAF) and entecavir for viral suppression with excellent safety profiles; switching strategies for patients on older agents
- Pegylated Interferon Therapy — For selected patients with high likelihood of HBsAg loss; combination strategies with NUCs
- Novel HBsAg-Targeting Therapies — Access to clinical trials evaluating RNA interference (RNAi) agents, capsid assembly modulators, and other novel HBV-targeting compounds aimed at achieving functional cure
- HBV Reactivation Prevention — Prophylaxis protocols for patients receiving immunosuppressive therapy, chemotherapy, or biologic agents
Hepatitis C: Cure for All
With the availability of pan-genotypic direct-acting antiviral (DAA) therapy, hepatitis C is now curable in >95% of patients regardless of genotype, prior treatment history, or cirrhosis status. Ruijin's hepatitis C program offers:
- Pan-Genotypic DAA Therapy — Sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) for all genotypes including genotype 3 and cirrhotic patients
- DAA-Experienced Patients — Salvage regimens for patients who have failed prior DAA therapy
- HCV/HIV Co-infection — Integrated management with HIV/AIDS service
- Post-SVR Surveillance — HCC surveillance and liver fibrosis monitoring after hepatitis C cure
Artificial Liver Support
For patients with acute liver failure or acute-on-chronic liver failure, Ruijin's department offers artificial liver support systems — extracorporeal liver support devices that temporarily replace liver function while the liver recovers or as a bridge to transplantation:
- Plasma Exchange — For acute liver failure and ACLF
- MARS (Molecular Adsorbent Recirculating System) — Albumin dialysis for liver failure with hepatic encephalopathy
- DPMAS (Double Plasma Molecular Adsorption System) — Combined plasma adsorption for liver failure
Why International Patients Choose Ruijin Infectious Disease & Hepatology
- Hepatitis B Expertise — National leadership in CHB management including access to novel HBsAg-targeting therapies in clinical trials
- Hepatitis C Cure Program — Pan-genotypic DAA therapy with >95% cure rates across all patient populations
- Cirrhosis Management — Comprehensive management of all cirrhosis complications including artificial liver support
- MDRO Infection Expertise — Access to novel antibiotics for carbapenem-resistant and other multidrug-resistant organisms
- Clinical Trial Access — Participation in trials evaluating novel HBV-targeting therapies for functional cure
- Cost-Effectiveness — World-class hepatology and infectious disease care at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your hepatology or infectious disease history, recent lab results (liver function, viral load, HBsAg, HCV RNA), imaging, biopsy reports, and current medications with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate specialist based on your condition — hepatitis B, hepatitis C, cirrhosis, HIV, or complex infection.
- Priority Scheduling — We secure a consultation with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near Ruijin Hospital, and Shanghai airport transfers.
- On-Site Concierge — Bilingual coordinators accompany you throughout your hospital visits, managing registration, translation, and communication.
- Diagnostic Support — Full coordination of liver biopsy, fibroscan, viral load testing, and other required investigations.
- Post-Treatment Follow-Up — Lab result translation, treatment response monitoring, and remote follow-up coordination after you return home.
Book a Consultation
If you are seeking expert hepatology or infectious disease care in Shanghai — whether for chronic hepatitis B or C, liver cirrhosis, HIV, a complex infection, or a second opinion on a challenging diagnosis — CMCS can arrange a specialist consultation with Ruijin Hospital's infectious disease and hepatology team.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 comentarios